| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | colony stimulating factor 2 | ||||
| GTO ID | GTC1861 |
| Trial ID | NCT03430687 |
| Disease | Bladder Urothelial Carcinoma |
| Altered gene | GMCSF |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Talimogene Laherparepvec|Imlygic|T-VEC|JS1 34.5-hGMCSF 47- pA- |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma |
| Year | 2018 |
| Country | United States |
| Company sponsor | University of California, San Francisco |
| Other ID(s) | 15521|NCI-2018-00109|15-17558|15521 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||